dihydroxyphenylalanine has been researched along with Sensitivity and Specificity in 111 studies
Dihydroxyphenylalanine: A beta-hydroxylated derivative of phenylalanine. The D-form of dihydroxyphenylalanine has less physiologic activity than the L-form and is commonly used experimentally to determine whether the pharmacological effects of LEVODOPA are stereospecific.
dopa : A hydroxyphenylalanine carrying hydroxy substituents at positions 3 and 4 of the benzene ring.
Sensitivity and Specificity: Binary classification measures to assess test results. Sensitivity or recall rate is the proportion of true positives. Specificity is the probability of correctly determining the absence of a condition. (From Last, Dictionary of Epidemiology, 2d ed)
| Excerpt | Relevance | Reference |
|---|---|---|
| "We performed a meta-analysis on published data on the diagnostic performance of fluorine-18 dihydroxyphenylalanine ((18)F-DOPA) positron emission tomography (PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI)." | 8.88 | Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis. ( Giordano, A; Mirk, P; Rufini, V; Treglia, G, 2012) |
| "To evaluate (18)F-fluorodihydroxyphenylalanine-positron emission tomography/ contrast-enhanced computed tomography ((18)F-DOPA PET/CT) for the detection of paragangliomas (PARA) without any patient selection, such as genetic predisposition for the development of these tumors, history of metastatic PARA or hormonal status." | 7.83 | Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma. ( Dudczak, R; El-Rabadi, K; Hacker, M; Karanikas, G; Mayerhofer, M; Mitterhauser, M; Nakuz, T; Scherer, T; Weber, M, 2016) |
| "Unaffected, mutation-positive relatives of index patients with hereditary paraganglioma syndromes were offered PET imaging with [(18)F]fluorodihydroxyphenylalanine and the incidence of pathological findings was retrospectively analysed in relation to mutations of the succinate dehydrogenase enzyme complex." | 7.79 | High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [18F]fluorodihydroxyphenylalanine PET. ( Bartsch, O; Fottner, C; Helisch, A; Lackner, KJ; Mann, WJ; Miederer, M; Musholt, TJ; Papaspyrou, K; Rossmann, H; Schreckenberger, M; Weber, MM, 2013) |
| "We aimed to elucidate the accuracy and limitations of [(18)F]-fluoro-L-dihydroxyphenylalanine ([(18) F]DOPA) positron emission tomography (PET) for Japanese patients with congenital hyperinsulinism." | 7.77 | Diagnostic accuracy of [¹⁸F]-fluoro-L-dihydroxyphenylalanine positron emission tomography scan for persistent congenital hyperinsulinism in Japan. ( Doi, R; Fukuyama, S; Kasai, T; Masue, M; Nishibori, H; Okamoto, S; Tokumi, T; Uemoto, S; Yorifuji, T; Yoshizawa, A, 2011) |
| "In detecting pheochromocytoma (PHEO), positron emission tomography (PET) with the radiolabelled amine precursor (18)F-fluorodihydroxyphenylalanine ((18)F-DOPA) offers excellent specificity, while computed tomography (CT) provides high sensitivity and ability to localize lesions; therefore, the combination of these modalities could be advantageous in this setting." | 7.76 | Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. ( Buck, AK; Dralle, H; Glatting, G; Karges, W; Luster, M; Mottaghy, FM; Neumaier, B; Pauls, S; Reske, SN; Solbach, C; Verburg, FA; Zeich, K, 2010) |
| "We performed a meta-analysis on published data on the diagnostic performance of fluorine-18 dihydroxyphenylalanine ((18)F-DOPA) positron emission tomography (PET) in diagnosing and localizing focal congenital hyperinsulinism (CHI)." | 4.88 | Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis. ( Giordano, A; Mirk, P; Rufini, V; Treglia, G, 2012) |
| "To evaluate (18)F-fluorodihydroxyphenylalanine-positron emission tomography/ contrast-enhanced computed tomography ((18)F-DOPA PET/CT) for the detection of paragangliomas (PARA) without any patient selection, such as genetic predisposition for the development of these tumors, history of metastatic PARA or hormonal status." | 3.83 | Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma. ( Dudczak, R; El-Rabadi, K; Hacker, M; Karanikas, G; Mayerhofer, M; Mitterhauser, M; Nakuz, T; Scherer, T; Weber, M, 2016) |
| "To compare MRI using perfusion and diffusion techniques with 6-[(18)F]-fluoro-L-3,4-dihydroxyphenylalanine ((18)F-FDOPA) positron emission tomography (PET) in the follow-up of low-grade gliomas (LGGs) and to identify the best imaging parameter to differentiate patients with different prognosis." | 3.83 | Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET. ( Bozzao, A; Cicone, F; Mancuso, V; Minniti, G; Napolitano, A; Romano, A; Rossi Espagnet, MC; Scaringi, C, 2016) |
| "We assessed the performance of 6-[(18)F]-fluoro-L-3,4-dihydroxyphenylalanine (F-DOPA) PET for differentiating radionecrosis (RN) from tumour progression (PD) in a population of patients with brain metastases, treated with stereotactic radiosurgery." | 3.81 | Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. ( Bozzao, A; Cicone, F; Maurizi Enrici, R; Minniti, G; Papa, A; Romano, A; Scaringi, C; Scopinaro, F; Tavanti, F, 2015) |
| "Nineteen patients with newly diagnosed high-grade gliomas underwent computed tomography (CT), gadolinium contrast-enhanced MRI, and (18)F-FDOPA PET/CT." | 3.79 | High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers. ( Benard, F; Chan, EK; Cheung, A; Hsu, F; Kosztyla, R; Ma, R; Moiseenko, V; Nichol, A; Wilson, D; Zhang, S, 2013) |
| "Unaffected, mutation-positive relatives of index patients with hereditary paraganglioma syndromes were offered PET imaging with [(18)F]fluorodihydroxyphenylalanine and the incidence of pathological findings was retrospectively analysed in relation to mutations of the succinate dehydrogenase enzyme complex." | 3.79 | High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [18F]fluorodihydroxyphenylalanine PET. ( Bartsch, O; Fottner, C; Helisch, A; Lackner, KJ; Mann, WJ; Miederer, M; Musholt, TJ; Papaspyrou, K; Rossmann, H; Schreckenberger, M; Weber, MM, 2013) |
| "We aimed to elucidate the accuracy and limitations of [(18)F]-fluoro-L-dihydroxyphenylalanine ([(18) F]DOPA) positron emission tomography (PET) for Japanese patients with congenital hyperinsulinism." | 3.77 | Diagnostic accuracy of [¹⁸F]-fluoro-L-dihydroxyphenylalanine positron emission tomography scan for persistent congenital hyperinsulinism in Japan. ( Doi, R; Fukuyama, S; Kasai, T; Masue, M; Nishibori, H; Okamoto, S; Tokumi, T; Uemoto, S; Yorifuji, T; Yoshizawa, A, 2011) |
| "In detecting pheochromocytoma (PHEO), positron emission tomography (PET) with the radiolabelled amine precursor (18)F-fluorodihydroxyphenylalanine ((18)F-DOPA) offers excellent specificity, while computed tomography (CT) provides high sensitivity and ability to localize lesions; therefore, the combination of these modalities could be advantageous in this setting." | 3.76 | Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma. ( Buck, AK; Dralle, H; Glatting, G; Karges, W; Luster, M; Mottaghy, FM; Neumaier, B; Pauls, S; Reske, SN; Solbach, C; Verburg, FA; Zeich, K, 2010) |
| "To assess the accuracy of 18F-fluoro-L-dihydroxyphenylalanine ([18F]-DOPA) PET scans to diagnose focal versus diffuse disease and to localize focal lesions in infants with congenital hyperinsulinism." | 3.74 | Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. ( Adzick, NS; Alavi, A; Freifelder, R; Ganguly, A; Hardy, OT; Hernandez-Pampaloni, M; Ruchelli, E; Saffer, JR; Stanley, CA; Suchi, M; Zhuang, H, 2007) |
| "To evaluate fluorine 18 ((18)F) dihydroxyphenylalanine (DOPA) whole-body positron emission tomography (PET) as a biochemical imaging approach for detection of pheochromocytomas." | 3.71 | Pheochromocytomas: detection with 18F DOPA whole body PET--initial results.. ( Altehoefer, C; Brink, I; Ghanem, N; Hoegerle, S; Manz, T; Moser, E; Neumann, HP; Nitzsche, E; Reincke, M, 2002) |
| "Differentiation between recurrence and radiation necrosis in patients with glioma is crucial, since the two entities have completely different management and prognosis." | 2.78 | 18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT. ( Bal, C; Bandopadhyaya, GP; Gupta, DK; Karunanithi, S; Khangembam, BC; Kumar, A; Kumar, R; Malhotra, A; Sharma, P, 2013) |
| "Information on evaluation of brain metastases is limited but encouraging." | 2.48 | Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT. ( Calabria, F; Chiaravalloti, A; Di Pietro, B; Grasso, C; Schillaci, O, 2012) |
| "With respect to Parkinson's disease PET and later SPECT allowed the number of dopaminergic neurons to be assessed in vivo." | 2.46 | [Nuclear medicine imaging in patients with Parkinson's syndrome: an update]. ( Schwarz, J, 2010) |
| "Paragangliomas are tumours that arise within the sympathetic nervous system originating from the neural crest." | 2.43 | Imaging of pheochromocytoma and paraganglioma. ( Bley, TA; Brink, I; Hoegerle, S; Klisch, J, 2005) |
| "The power of (18)F-FDOPA PET to predict disease progression was evaluated with the Kaplan-Meier and Cox regression methods." | 1.40 | (18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment. ( Allen-Auerbach, M; Chen, W; Czernin, J; DeSalles, AA; Lizarraga, KJ; Phelps, ME; Yong, WH, 2014) |
| "In Canada, staging of carcinoid tumors is largely based on computed tomography (CT) imaging sometimes complemented with somatostatin receptor scintigraphy (SRS)." | 1.38 | PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting. ( Chirakal, R; Gulenchyn, KY; Jager, PL; Major, P; Reid, R; Yakemchuk, VN, 2012) |
| "We report the case of a carcinoid tumor with suspicion of recurrence on biology." | 1.36 | [Recurrent carcinoid tumor and 18F-DOPA PET]. ( Cavet, M; Dousset, B; Faraggi, M; Hignette, C; Modis, C; Richard, B; Tenenbaum, F, 2010) |
| "Diagnosing Parkinson's disease (PD) on clinical grounds may be difficult, especially in the early stages of the disease." | 1.35 | Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls. ( Dierckx, RA; Eshuis, SA; Jager, PL; Jonkman, S; Leenders, KL; Maguire, RP, 2009) |
| "(68)Ga-DOTA-TATE PET delineated metastases in 54 of 55 positive metastatic tumour regions in contrast to 29 of 55 delineated by (18)F-DOPA PET." | 1.35 | Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours. ( Auernhammer, CJ; Bartenstein, P; Göke, B; Haug, A; Pöpperl, G; Schmidt, G; Tiling, R; Wängler, B, 2009) |
| "Successful treatment of pheochromocytoma requires accurate diagnosis and localization of tumors." | 1.35 | 18F-FDOPA PET and PET/CT accurately localize pheochromocytomas. ( Agopian, VG; Auerbach, MS; Benz, MR; Czernin, JG; Dumont, RA; Imani, F; Lai, CK; Walter, MA; Yeh, MW, 2009) |
| "In all carcinoid patients (18)F-DOPA PET and (11)C-5-HTP PET detected more lesions than SRS (P < ." | 1.35 | Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography. ( Brouwers, AH; de Vries, EG; Elsinga, PH; Jager, PL; Kema, IP; Koopmans, KP; Neels, OC; Sluiter, WJ; Vanghillewe, K, 2008) |
| "Conversely, in noncarcinoid tumors, the extent of the disease was more accurately evaluated in all cases by (111)In-pentetreotide SRS than by (18)F-FDOPA PET." | 1.33 | Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors? ( Aide, N; de Beco, V; Grahek, D; Grangé, JD; Gutman, F; Kerrou, K; Lotz, JP; Montravers, F; Ruszniewski, P; Talbot, JN, 2006) |
| "Thirty two patients with Parkinson's disease (mean age 58 (SD 13) years, mean duration 39 (SD 33) months) were assessed with [18F]dopa PET and UPDRS scoring on two occasions a mean of 18 (SD 6) months apart." | 1.30 | Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET. ( Bailey, DL; Brooks, DJ; Morrish, PK; Rakshi, JS; Sawle, GV, 1998) |
| "Pretreatment with entacapone (OR-611), a peripheral catechol O-methyl-transferase (COMT) inhibitor, greatly reduces the plasma 3OMFD fraction and provides an ideal situation to evaluate the contribution of the plasma 3OMFD fraction in several kinetic models of FDOPA uptake." | 1.29 | Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis. ( Belakhlef, A; Chaly, T; Dahl, R; Dhawan, V; Eidelberg, D; Ishikawa, T; Mandel, F; Margouleff, C; Robeson, W, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (0.90) | 18.7374 |
| 1990's | 8 (7.21) | 18.2507 |
| 2000's | 49 (44.14) | 29.6817 |
| 2010's | 47 (42.34) | 24.3611 |
| 2020's | 6 (5.41) | 2.80 |
| Authors | Studies |
|---|---|
| Bertaux, M | 1 |
| Berenbaum, A | 1 |
| Di Stefano, AL | 1 |
| Rozenblum, L | 1 |
| Soret, M | 1 |
| Bergeret, S | 1 |
| Hoang-Xuan, K | 1 |
| Tainturier, LE | 1 |
| Sgard, B | 1 |
| Habert, MO | 1 |
| Delattre, JY | 1 |
| Dehais, C | 1 |
| Idbaih, A | 1 |
| Pyatigorskaya, N | 1 |
| Kas, A | 2 |
| Lersy, F | 1 |
| Kremer, S | 1 |
| Chibbaro, S | 2 |
| Namer, IJ | 3 |
| Bund, C | 2 |
| Goldfarb, L | 1 |
| Iep, A | 1 |
| Chawki, MB | 1 |
| Nguyen, L | 1 |
| Lun, F | 1 |
| Carpentier, AAN | 1 |
| de Recondo, A | 1 |
| Blin, J | 1 |
| Bourdinaud, V | 1 |
| Morin, L | 1 |
| Andriatsiferana, H | 1 |
| Ferreira, A | 1 |
| Deschiens, AM | 1 |
| Brulon, V | 1 |
| Comtat, C | 1 |
| Lebon, V | 1 |
| Besson, FL | 1 |
| Darcourt, J | 2 |
| Chardin, D | 1 |
| Bourg, V | 1 |
| Gal, J | 1 |
| Schiappa, R | 1 |
| Blonski, M | 1 |
| Koulibaly, PM | 2 |
| Almairac, F | 1 |
| Mondot, L | 1 |
| Le Jeune, F | 1 |
| Collombier, L | 1 |
| Taillandier, L | 1 |
| Verger, A | 2 |
| Todeschi, J | 1 |
| Cebula, H | 1 |
| Lhermitte, B | 1 |
| Pin, Y | 1 |
| Lefebvre, F | 1 |
| Proust, F | 1 |
| Barachini, O | 1 |
| Bernt, R | 1 |
| Mirzaei, S | 1 |
| Pirich, C | 2 |
| Hergan, K | 1 |
| Zandieh, S | 1 |
| Veenstra, EB | 1 |
| de Groot, DJA | 1 |
| Brouwers, AH | 3 |
| Walenkamp, AME | 1 |
| Noordzij, W | 1 |
| Ginet, M | 1 |
| Cuny, T | 1 |
| Schmitt, E | 1 |
| Marie, PY | 1 |
| Moreau, A | 1 |
| Giraudet, AL | 1 |
| Kryza, D | 1 |
| Borson-Chazot, F | 1 |
| Bournaud, C | 1 |
| Mognetti, T | 1 |
| Lifante, JC | 1 |
| Combemale, P | 1 |
| Giammarile, F | 1 |
| Houzard, C | 1 |
| Qu, Z | 1 |
| Na, W | 1 |
| Liu, X | 1 |
| Liu, H | 1 |
| Su, X | 1 |
| Qu, F | 1 |
| Huang, W | 1 |
| You, J | 1 |
| Youland, RS | 1 |
| Pafundi, DH | 1 |
| Brinkmann, DH | 1 |
| Lowe, VJ | 1 |
| Morris, JM | 1 |
| Kemp, BJ | 1 |
| Hunt, CH | 1 |
| Giannini, C | 1 |
| Parney, IF | 1 |
| Laack, NN | 1 |
| Rasul, S | 1 |
| Hartenbach, S | 1 |
| Rebhan, K | 1 |
| Göllner, A | 1 |
| Karanikas, G | 5 |
| Mayerhoefer, M | 1 |
| Mazal, P | 1 |
| Hacker, M | 2 |
| Hartenbach, M | 1 |
| Brammen, L | 1 |
| Niederle, MB | 1 |
| Riss, P | 1 |
| Scheuba, C | 1 |
| Selberherr, A | 1 |
| Bodner, G | 1 |
| Koperek, O | 1 |
| Niederle, B | 1 |
| Lugat, A | 1 |
| Drui, D | 1 |
| Mirallié, E | 1 |
| Kraeber-Bodéré, F | 1 |
| Ansquer, C | 1 |
| Balogova, S | 2 |
| Talbot, JN | 3 |
| Nataf, V | 1 |
| Michaud, L | 1 |
| Huchet, V | 1 |
| Kerrou, K | 3 |
| Montravers, F | 3 |
| Karunanithi, S | 3 |
| Sharma, P | 3 |
| Kumar, A | 3 |
| Khangembam, BC | 3 |
| Bandopadhyaya, GP | 2 |
| Kumar, R | 4 |
| Gupta, DK | 3 |
| Malhotra, A | 2 |
| Bal, C | 3 |
| Goenka, A | 1 |
| Zanzi, I | 1 |
| Warner, RR | 1 |
| Kosztyla, R | 1 |
| Chan, EK | 1 |
| Hsu, F | 1 |
| Wilson, D | 1 |
| Ma, R | 1 |
| Cheung, A | 1 |
| Zhang, S | 1 |
| Moiseenko, V | 1 |
| Benard, F | 1 |
| Nichol, A | 1 |
| Lizarraga, KJ | 1 |
| Allen-Auerbach, M | 1 |
| Czernin, J | 4 |
| DeSalles, AA | 1 |
| Yong, WH | 1 |
| Phelps, ME | 2 |
| Chen, W | 4 |
| Ballal, S | 1 |
| Rong, Y | 1 |
| Vernaleken, I | 1 |
| Winz, OH | 1 |
| Goedicke, A | 1 |
| Mottaghy, FM | 2 |
| Kops, ER | 1 |
| Cicone, F | 2 |
| Minniti, G | 2 |
| Romano, A | 2 |
| Papa, A | 1 |
| Scaringi, C | 2 |
| Tavanti, F | 1 |
| Bozzao, A | 2 |
| Maurizi Enrici, R | 1 |
| Scopinaro, F | 1 |
| Schiazza, A | 1 |
| Sapin, N | 1 |
| Dufour, M | 1 |
| Ouvrier, MJ | 1 |
| Benisvy, D | 1 |
| Fontana, X | 1 |
| Morana, G | 1 |
| Piccardo, A | 2 |
| Puntoni, M | 1 |
| Nozza, P | 1 |
| Cama, A | 1 |
| Raso, A | 1 |
| Mascelli, S | 1 |
| Massollo, M | 1 |
| Milanaccio, C | 1 |
| Garrè, ML | 1 |
| Rossi, A | 1 |
| Knie, B | 1 |
| Plotkin, M | 1 |
| Zschieschang, P | 1 |
| Prasad, V | 1 |
| Moskopp, D | 1 |
| El-Rabadi, K | 1 |
| Weber, M | 2 |
| Mayerhofer, M | 1 |
| Nakuz, T | 1 |
| Scherer, T | 1 |
| Mitterhauser, M | 1 |
| Dudczak, R | 2 |
| Rossi Espagnet, MC | 1 |
| Mancuso, V | 1 |
| Napolitano, A | 1 |
| Detour, J | 1 |
| Pierre, A | 1 |
| Boisson, F | 1 |
| Kreutter, G | 1 |
| Lavaux, T | 1 |
| Kessler, L | 1 |
| Brasse, D | 1 |
| Marchand, P | 1 |
| Imperiale, A | 1 |
| Ito, T | 1 |
| Jensen, RT | 1 |
| Ledezma, CJ | 1 |
| Sai, V | 1 |
| Freitas, B | 1 |
| Cloughesy, T | 3 |
| Pope, W | 2 |
| Zocca, F | 1 |
| Lomolino, G | 1 |
| Lante, A | 1 |
| Bose, SK | 1 |
| Turkheimer, FE | 1 |
| Howes, OD | 1 |
| Mehta, MA | 1 |
| Cunliffe, R | 1 |
| Stokes, PR | 1 |
| Grasby, PM | 1 |
| Eshuis, SA | 1 |
| Jager, PL | 5 |
| Maguire, RP | 1 |
| Jonkman, S | 1 |
| Dierckx, RA | 2 |
| Leenders, KL | 1 |
| Haug, A | 1 |
| Auernhammer, CJ | 1 |
| Wängler, B | 1 |
| Tiling, R | 1 |
| Schmidt, G | 1 |
| Göke, B | 1 |
| Bartenstein, P | 1 |
| Pöpperl, G | 1 |
| Beheshti, M | 1 |
| Pöcher, S | 1 |
| Vali, R | 1 |
| Waldenberger, P | 1 |
| Broinger, G | 1 |
| Nader, M | 1 |
| Kohlfürst, S | 1 |
| Dralle, H | 2 |
| Langsteger, W | 1 |
| Imani, F | 2 |
| Agopian, VG | 1 |
| Auerbach, MS | 1 |
| Walter, MA | 2 |
| Benz, MR | 1 |
| Dumont, RA | 1 |
| Lai, CK | 1 |
| Czernin, JG | 1 |
| Yeh, MW | 1 |
| Fiebrich, HB | 1 |
| Kerstens, MN | 1 |
| Pijl, ME | 1 |
| Kema, IP | 2 |
| de Jong, JR | 1 |
| Elsinga, PH | 2 |
| van der Wal, JE | 1 |
| Sluiter, WJ | 2 |
| de Vries, EG | 3 |
| Links, TP | 1 |
| Pestourie, C | 1 |
| Thézé, B | 1 |
| Kuhnast, B | 1 |
| Le Helleix, S | 1 |
| Gombert, K | 1 |
| Dollé, F | 1 |
| Tavitian, B | 1 |
| Ducongé, F | 1 |
| Ambrosini, V | 5 |
| Marzola, MC | 2 |
| Rubello, D | 6 |
| Fanti, S | 7 |
| Capito, C | 1 |
| Khen-Dunlop, N | 1 |
| Ribeiro, MJ | 4 |
| Brunelle, F | 2 |
| Aigrain, Y | 1 |
| Crétolle, C | 1 |
| Jaubert, F | 2 |
| De Lonlay, P | 2 |
| Nihoul-Fékété, C | 2 |
| Luster, M | 1 |
| Karges, W | 1 |
| Zeich, K | 1 |
| Pauls, S | 1 |
| Verburg, FA | 1 |
| Glatting, G | 1 |
| Buck, AK | 1 |
| Solbach, C | 1 |
| Neumaier, B | 1 |
| Reske, SN | 1 |
| Cavet, M | 1 |
| Tenenbaum, F | 1 |
| Hignette, C | 1 |
| Modis, C | 1 |
| Richard, B | 1 |
| Faraggi, M | 1 |
| Dousset, B | 1 |
| Zemskova, MS | 1 |
| Gundabolu, B | 1 |
| Sinaii, N | 1 |
| Chen, CC | 1 |
| Carrasquillo, JA | 1 |
| Whatley, M | 1 |
| Chowdhury, I | 1 |
| Gharib, AM | 1 |
| Nieman, LK | 1 |
| Pelizzo, MR | 1 |
| Ferdeghini, M | 1 |
| Toniato, A | 1 |
| Massaro, A | 1 |
| Gross, MD | 1 |
| Al-Nahhas, A | 3 |
| Tripathi, M | 1 |
| Sharma, R | 1 |
| D'Souza, M | 1 |
| Jaimini, A | 1 |
| Panwar, P | 1 |
| Varshney, R | 1 |
| Datta, A | 1 |
| Kumar, N | 1 |
| Garg, G | 1 |
| Singh, D | 1 |
| Grover, RK | 1 |
| Mishra, AK | 1 |
| Mondal, A | 1 |
| Schiesser, M | 2 |
| Veit-Haibach, P | 2 |
| Muller, MK | 1 |
| Bauerfeind, P | 1 |
| Hany, T | 1 |
| Clavien, PA | 2 |
| Soyka, J | 1 |
| Strobel, K | 1 |
| Schaefer, NG | 1 |
| Hesselmann, R | 1 |
| Hany, TF | 1 |
| Schwarz, J | 1 |
| Fueger, BJ | 1 |
| Silverman, DH | 3 |
| Geist, CL | 1 |
| Schiepers, C | 2 |
| Nghiemphu, P | 1 |
| Lai, A | 1 |
| Dowson, N | 1 |
| Bourgeat, P | 1 |
| Rose, S | 1 |
| Daglish, M | 1 |
| Smith, J | 1 |
| Fay, M | 1 |
| Coulthard, A | 1 |
| Winter, C | 1 |
| MacFarlane, D | 1 |
| Thomas, P | 1 |
| Crozier, S | 1 |
| Salvado, O | 1 |
| Matsubara, K | 1 |
| Watabe, H | 1 |
| Kumakura, Y | 2 |
| Hayashi, T | 1 |
| Endres, CJ | 1 |
| Minato, K | 1 |
| Iida, H | 1 |
| Masue, M | 1 |
| Nishibori, H | 1 |
| Fukuyama, S | 1 |
| Yoshizawa, A | 1 |
| Okamoto, S | 1 |
| Doi, R | 1 |
| Uemoto, S | 1 |
| Tokumi, T | 1 |
| Kasai, T | 1 |
| Yorifuji, T | 1 |
| Martiniova, L | 1 |
| Cleary, S | 1 |
| Lai, EW | 1 |
| Kiesewetter, DO | 1 |
| Seidel, J | 1 |
| Dawson, LF | 1 |
| Phillips, JK | 1 |
| Thomasson, D | 1 |
| Chen, X | 1 |
| Eisenhofer, G | 2 |
| Powers, JF | 1 |
| Kvetnansky, R | 1 |
| Pacak, K | 1 |
| Yakemchuk, VN | 1 |
| Chirakal, R | 1 |
| Reid, R | 1 |
| Major, P | 1 |
| Gulenchyn, KY | 1 |
| Lopci, E | 1 |
| Nanni, C | 5 |
| Altrinetti, V | 1 |
| Garaventa, A | 1 |
| Pession, A | 1 |
| Cistaro, A | 1 |
| Chiti, A | 1 |
| Villavecchia, G | 1 |
| Calabria, F | 1 |
| Chiaravalloti, A | 1 |
| Di Pietro, B | 1 |
| Grasso, C | 1 |
| Schillaci, O | 1 |
| Treglia, G | 2 |
| Cocciolillo, F | 1 |
| Di Nardo, F | 1 |
| Poscia, A | 1 |
| de Waure, C | 1 |
| Giordano, A | 2 |
| Rufini, V | 2 |
| Asakawa, T | 1 |
| Sugiyama, K | 1 |
| Akamine, S | 1 |
| Yokoyama, C | 1 |
| Shukuri, M | 1 |
| Mizuma, H | 1 |
| Tsukada, H | 1 |
| Onoe, H | 1 |
| Namba, H | 1 |
| Mirk, P | 1 |
| Lu, MY | 1 |
| Liu, YL | 1 |
| Chang, HH | 1 |
| Jou, ST | 1 |
| Yang, YL | 1 |
| Lin, KH | 1 |
| Lin, DT | 1 |
| Lee, YL | 1 |
| Lee, H | 1 |
| Wu, PY | 1 |
| Luo, TY | 1 |
| Shen, LH | 1 |
| Huang, SF | 1 |
| Liao, YF | 1 |
| Hsu, WM | 1 |
| Tzen, KY | 1 |
| Miederer, M | 1 |
| Fottner, C | 1 |
| Rossmann, H | 1 |
| Helisch, A | 1 |
| Papaspyrou, K | 1 |
| Bartsch, O | 1 |
| Mann, WJ | 1 |
| Musholt, TJ | 1 |
| Weber, MM | 1 |
| Lackner, KJ | 1 |
| Schreckenberger, M | 1 |
| Ha, PT | 1 |
| Van Schepdael, A | 1 |
| Hauta-Aho, T | 1 |
| Roets, E | 1 |
| Hoogmartens, J | 1 |
| Hoegerle, S | 4 |
| Ghanem, N | 3 |
| Altehoefer, C | 3 |
| Schipper, J | 1 |
| Brink, I | 3 |
| Moser, E | 3 |
| Neumann, HP | 2 |
| Beuthien-Baumann, B | 2 |
| Bredow, J | 2 |
| Burchert, W | 1 |
| Füchtner, F | 2 |
| Bergmann, R | 1 |
| Alheit, HD | 1 |
| Reiss, G | 1 |
| Hliscs, R | 1 |
| Steinmeier, R | 1 |
| Franke, WG | 1 |
| Johannsen, B | 1 |
| Kotzerke, J | 2 |
| Huang, WS | 1 |
| Chiang, YH | 1 |
| Lin, JC | 1 |
| Chou, YH | 1 |
| Cheng, CY | 1 |
| Liu, RS | 1 |
| Jacob, T | 1 |
| Grahek, D | 2 |
| Younsi, N | 1 |
| Aide, N | 2 |
| Colombet, C | 1 |
| De Beco, V | 2 |
| WERLE, E | 1 |
| AURES, D | 1 |
| Pirker, W | 1 |
| Becherer, A | 2 |
| Szabó, M | 2 |
| Zettinig, G | 1 |
| Asenbaum, S | 1 |
| Marosi, C | 1 |
| Henk, C | 1 |
| Wunderbaldinger, P | 2 |
| Czech, T | 1 |
| Wadsak, W | 1 |
| Kletter, K | 2 |
| Heiss, WD | 1 |
| Hilker, R | 1 |
| Whone, AL | 1 |
| Bailey, DL | 2 |
| Remy, P | 1 |
| Pavese, N | 1 |
| Brooks, DJ | 2 |
| Angelberger, P | 2 |
| Raderer, M | 1 |
| Kurtaran, A | 1 |
| Bouilleret, V | 2 |
| Semah, F | 2 |
| Biraben, A | 2 |
| Taussig, D | 1 |
| Chassoux, F | 2 |
| Syrota, A | 1 |
| Klisch, J | 1 |
| Bley, TA | 1 |
| Gjedde, A | 1 |
| Danielsen, EH | 1 |
| Christensen, S | 1 |
| Cumming, P | 1 |
| Fireman-Shoresh, S | 1 |
| Turyan, I | 1 |
| Mandler, D | 1 |
| Avnir, D | 1 |
| Marx, S | 1 |
| Pan, XB | 1 |
| Wright, TG | 1 |
| Leong, FJ | 1 |
| McLaughlin, RA | 1 |
| Declerck, JM | 1 |
| Delaloye, S | 1 |
| Kamdar, N | 1 |
| Satyamurthy, N | 1 |
| Honer, M | 1 |
| Hengerer, B | 1 |
| Blagoev, M | 1 |
| Hintermann, S | 1 |
| Waldmeier, P | 1 |
| Schubiger, PA | 1 |
| Ametamey, SM | 1 |
| Ruszniewski, P | 1 |
| Gutman, F | 1 |
| Grangé, JD | 1 |
| Lotz, JP | 1 |
| Koopmans, KP | 2 |
| Sperling, MA | 1 |
| Hardy, OT | 1 |
| Hernandez-Pampaloni, M | 1 |
| Saffer, JR | 1 |
| Suchi, M | 1 |
| Ruchelli, E | 1 |
| Zhuang, H | 1 |
| Ganguly, A | 1 |
| Freifelder, R | 1 |
| Adzick, NS | 1 |
| Alavi, A | 1 |
| Stanley, CA | 1 |
| Strumpf, A | 1 |
| Zessin, J | 1 |
| Tomassetti, P | 2 |
| Campana, D | 2 |
| Castellucci, P | 2 |
| Farsad, M | 1 |
| Montini, G | 2 |
| Franchi, R | 2 |
| Boddaert, N | 1 |
| Bellanné-Chantelot, C | 1 |
| Bourgeois, S | 1 |
| Valayannopoulos, V | 1 |
| Delzescaux, T | 1 |
| Mantzaridez, M | 1 |
| Trebossen, R | 1 |
| Chen, Y | 1 |
| Guo, C | 1 |
| Lim, L | 1 |
| Cheong, S | 1 |
| Zhang, Q | 1 |
| Tang, K | 1 |
| Reboud, J | 1 |
| Lee, MK | 1 |
| Kumar, AP | 1 |
| Jin, D | 1 |
| Lee, YI | 1 |
| Goldstein, DS | 1 |
| Holmes, C | 1 |
| Bentho, O | 1 |
| Sato, T | 1 |
| Moak, J | 1 |
| Sharabi, Y | 1 |
| Imrich, R | 1 |
| Conant, S | 1 |
| Eldadah, BA | 1 |
| Neels, OC | 1 |
| Vanghillewe, K | 1 |
| Rizzello, A | 1 |
| Enochs, WS | 1 |
| Nilges, MJ | 1 |
| Swartz, HM | 1 |
| Steiner, U | 1 |
| Schliemann, W | 1 |
| Strack, D | 1 |
| Róna, K | 1 |
| Ary, K | 1 |
| Gachályi, B | 1 |
| Klebovich, I | 1 |
| Ishikawa, T | 1 |
| Dhawan, V | 1 |
| Chaly, T | 1 |
| Robeson, W | 1 |
| Belakhlef, A | 1 |
| Mandel, F | 1 |
| Dahl, R | 1 |
| Margouleff, C | 1 |
| Eidelberg, D | 1 |
| Hooper, D | 1 |
| Kawamura, M | 1 |
| Hoffman, B | 1 |
| Kopin, IJ | 1 |
| Hunyady, B | 1 |
| Mezey, E | 1 |
| Qu, Y | 1 |
| Moons, L | 1 |
| Vandesande, F | 1 |
| Morrish, PK | 2 |
| Rakshi, JS | 1 |
| Sawle, GV | 1 |
| Serebrovskaya, TV | 1 |
| Karaban, IN | 1 |
| Kolesnikova, EE | 1 |
| Mishunina, TM | 1 |
| Swanson, RJ | 1 |
| Beloshitsky, PV | 1 |
| Ilyin, VN | 1 |
| Krasuk, AN | 1 |
| Safronova, OS | 1 |
| Kuzminskaya, LA | 1 |
| Dimitrakopoulou-Strauss, A | 1 |
| Strauss, LG | 1 |
| Burger, C | 1 |
| Koehler, G | 1 |
| Waller, CF | 1 |
| Scheruebl, H | 1 |
| Nitzsche, E | 2 |
| Harth, R | 1 |
| Gerlach, M | 1 |
| Riederer, P | 1 |
| Götz, ME | 1 |
| Manz, T | 1 |
| Reincke, M | 1 |
| Kvaternik, H | 1 |
| Hammerschmidt, F | 1 |
| Simovc, BP | 1 |
| Steinbach, J | 1 |
| Bostwick, JR | 1 |
| Le, WD | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of 18F-Fluciclovine PET-MRI to Differentiate Tumor Progression From Post-treatment Changes in Pediatric High-grade Glioma (HGG)[NCT05553041] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2023-08-07 | Recruiting | ||
| Evaluation of 18F-Fluciclovine PET-MRI as a Biomarker of Response in Pediatric and Young Adult Patients With Low Grade Gliomas (LGG)[NCT05555550] | Early Phase 1 | 30 participants (Anticipated) | Interventional | 2024-01-31 | Not yet recruiting | ||
| Using 3,4-dihydroxy-6-[18F]-Fluoro-l-phenylalanine ( [18F]FDOPA) PET/CT to Monitor the Effectiveness of Fetal Dopaminergic Grafts in Parkinson Disease Patients[NCT02538315] | 18 participants (Actual) | Observational | 2016-10-31 | Terminated (stopped due to lack of patients due to COVID) | |||
| Effect of Nano-PSO in Patients With Parkinson's Disease: Clinical Efficacy and Results in Molecular Imaging.[NCT05142085] | 170 participants (Anticipated) | Interventional | 2021-09-20 | Enrolling by invitation | |||
| Imaging After Stereotactic Radiosurgery for Brain Metastases or Primary Tumor Can Hybrid PET-MRI Differentiate Between Radiation Effects and Disease ?[NCT03068520] | 140 participants (Anticipated) | Interventional | 2017-03-01 | Recruiting | |||
| Localization of Focal Forms of Hyperinsulinism of Infancy With 18F-labeled L-fluoro-DOPA PET Scan[NCT00674440] | Phase 2 | 106 participants (Actual) | Interventional | 2004-12-31 | Completed | ||
| The Use of Fluorodopa F 18 Positron Emission Tomography Combined With Computed Tomography in Congenital Hyperinsulinism and Insulinoma[NCT02021604] | Phase 1 | 250 participants (Anticipated) | Interventional | 2013-10-09 | Recruiting | ||
| A Phase II Safety and Efficacy Study of 18F-L-Fluoro-DOPA PET/CT Scan Localization of Focal Pancreatic Lesions in Children With Hyperinsulinemic Hypoglycemia[NCT01468454] | Phase 2 | 130 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| A Single-blinded Assessment of the Short-term Effects of Cabergoline vs. Carbidopa/Levodopa on SPECT Dopamine Transporter Density in Out-patient Subjects With Parkinson's Disease[NCT00129181] | 30 participants (Actual) | Interventional | 2005-01-31 | Completed | |||
| Investigating Effects of Short-term Treatment With Pramipexole or Levodopa on [123I]B-CIT and SPECT Imaging in Early Parkinson's[NCT00096720] | Phase 2 | 112 participants (Actual) | Interventional | 2004-02-29 | Completed | ||
| Screening Evaluations for Neurologic Syndromes: Olfactory Testing in Relatives of Parkinson's Disease Patients[NCT00096876] | 600 participants (Anticipated) | Observational | 2004-10-31 | Completed | |||
| Parkinson Associated Risk Factor Study (PARS): Evaluating Potential Screening Tools for Parkinson Disease[NCT00387075] | Phase 2 | 3,000 participants (Anticipated) | Interventional | 2006-11-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of Participants with Adverse Events (NCT00674440)
Timeframe: 72 hours maximum or prior to pancreatic surgery
| Intervention | Participants (Count of Participants) |
|---|---|
| All Subjects Who Had PET | 0 |
Comparison of PET scan results with outcome of surgery and histopathology results confirmed as focal or diffuse (NCT00674440)
Timeframe: up to 1 month post surgical intervention
| Intervention | Participants (Count of Participants) | |||
|---|---|---|---|---|
| True Negatives (PET diffuse/surgery diffuse) | False negatives (PET diffuse/surgery focal): | False positives (PET focal/surgery diffuse): | True positives (PET focal/surgery focal): | |
| Subjects Who Had PET and Surgery | 40 | 6 | 3 | 46 |
"To further evaluate the safety of 18-labeled L-fluorodeoxyphenylalanine (18F-DOPA) PET/CT imaging in infants and children with congenital hyperinsulinism~- subjects are monitored clinically for any signs or symptoms of adverse events for 72 hours post PET. Adverse events are documented and followed to resolution" (NCT01468454)
Timeframe: evaluated with 72 hours or prior to pancreatic surgery (if any)
| Intervention | Participants (Count of Participants) |
|---|---|
| (18F-DOPA) PET/CT Imaging | 0 |
To determine the sensitivity and specificity of 18F-DOPA PET/CT for the detection of a focal pancreatic lesion in infants and children with poorly controlled hyperinsulinemic hypoglycemia. (NCT01468454)
Timeframe: Surgery typically occured within a week post PET
| Intervention | cases (Number) | |||
|---|---|---|---|---|
| True Negatives (PET diffuse/surgery diffuse) | False negatives (PET diffuse/surgery focal): | False positives (PET focal/surgery diffuse): | True positives (PET focal/surgery focal): | |
| PET/CT Imaging vs Surgical Result | 34 | 10 | 4 | 52 |
9 reviews available for dihydroxyphenylalanine and Sensitivity and Specificity
| Article | Year |
|---|---|
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.
Topics: 3-Iodobenzylguanidine; Bronchial Neoplasms; Carcinoma, Merkel Cell; Dihydroxyphenylalanine; Fluorode | 2013 |
18F-FDOPA PET for the diagnosis of parkinsonian syndromes.
Topics: Brain; Dihydroxyphenylalanine; Disease Progression; Humans; Image Processing, Computer-Assisted; Par | 2014 |
Molecular imaging in neuroendocrine tumors: recent advances, controversies, unresolved issues, and roles in management.
Topics: Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Glucagon-Like Peptide 1; Humans; Molecular Im | 2017 |
[Nuclear medicine imaging in patients with Parkinson's syndrome: an update].
Topics: Animals; Brain; Dihydroxyphenylalanine; Disease Progression; Dopamine; Energy Metabolism; Fluorodeox | 2010 |
Molecular imaging of brain tumors with 18F-DOPA PET and PET/CT.
Topics: Brain Neoplasms; Dihydroxyphenylalanine; Fluorine Radioisotopes; Humans; Magnetic Resonance Imaging; | 2012 |
Detection rate of recurrent medullary thyroid carcinoma using fluorine-18 dihydroxyphenylalanine positron emission tomography: a meta-analysis.
Topics: Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Humans; Neoplasm Recurrence, Local; Positron-Emis | 2012 |
Diagnostic performance of fluorine-18-dihydroxyphenylalanine positron emission tomography in diagnosing and localizing the focal form of congenital hyperinsulinism: a meta-analysis.
Topics: Congenital Hyperinsulinism; Dihydroxyphenylalanine; Evidence-Based Medicine; Humans; Positron-Emissi | 2012 |
The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson's disease.
Topics: Brain; Diagnosis, Differential; Dihydroxyphenylalanine; Disease Progression; Humans; Magnetic Resona | 2004 |
Imaging of pheochromocytoma and paraganglioma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Huma | 2005 |
17 trials available for dihydroxyphenylalanine and Sensitivity and Specificity
| Article | Year |
|---|---|
Prospective trial evaluating the sensitivity and specificity of 3,4-dihydroxy-6-[18F]-fluoro-L-phenylalanine (18F-DOPA) PET and MRI in patients with recurrent gliomas.
Topics: Adolescent; Adult; Brain; Brain Neoplasms; Contrast Media; Dihydroxyphenylalanine; Female; Glioma; H | 2018 |
18F-FDOPA PET/CT for detection of recurrence in patients with glioma: prospective comparison with 18F-FDG PET/CT.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; G | 2013 |
18F-DOPA PET/CT in neuroblastoma: comparison of conventional imaging with CT/MR.
Topics: Child; Dihydroxyphenylalanine; Female; Humans; Magnetic Resonance Imaging; Male; Multimodal Imaging; | 2012 |
18F-DOPA positron emission tomography for the detection of glomus tumours.
Topics: Adult; Aged; Carotid Body Tumor; Dihydroxyphenylalanine; Female; Glomus Tumor; Humans; Male; Middle | 2003 |
3-O-methyl-6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging.
Topics: Adult; Aged; Body Burden; Brain Neoplasms; Dihydroxyphenylalanine; Female; Humans; Male; Metabolic C | 2003 |
Crossover study of (99m)Tc-TRODAT-1 SPECT and (18)F-FDOPA PET in Parkinson's disease patients.
Topics: Aged; Corpus Striatum; Cross-Over Studies; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged | 2003 |
Positron emission tomography with [(18)F]FDOPA and [(18)F]FDG in the imaging of small cell lung carcinoma: preliminary results.
Topics: Adult; Aged; Carcinoma, Small Cell; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Humans; | 2003 |
Brain tumour imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine.
Topics: Adult; Aged; Brain Neoplasms; Dihydroxyphenylalanine; Female; Humans; Male; Methionine; Middle Aged; | 2003 |
A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study.
Topics: Algorithms; Antiparkinson Agents; Canada; Dihydroxyphenylalanine; Dopamine Agents; France; Germany; | 2004 |
Imaging of advanced neuroendocrine tumors with (18)F-FDOPA PET.
Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Indium Radioisotopes; Male; | 2004 |
Involvement of the basal ganglia in refractory epilepsy: an 18F-fluoro-L-DOPA PET study using 2 methods of analysis.
Topics: Adult; Algorithms; Anticonvulsants; Basal Ganglia; Brain Mapping; Dihydroxyphenylalanine; Drug Resis | 2005 |
Dopamine storage capacity in caudate and putamen of patients with early Parkinson's disease: correlation with asymmetry of motor symptoms.
Topics: Aged; Brain; Caudate Nucleus; Dihydroxyphenylalanine; Dopamine; Fluorine Radioisotopes; Functional L | 2006 |
Improving influx constant and ratio estimation in FDOPA brain PET analysis for Parkinson's disease.
Topics: Brain; Brain Mapping; Dihydroxyphenylalanine; Female; Humans; Image Enhancement; Image Interpretatio | 2005 |
18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy.
Topics: Adult; Aged; Brain Neoplasms; California; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Hu | 2006 |
Role of 18F-dopa PET/CT imaging in the management of patients with 111In-pentetreotide negative GEP tumours.
Topics: Adult; Aged; Aged, 80 and over; Biopsy, Needle; Digestive System Neoplasms; Dihydroxyphenylalanine; | 2007 |
Basal ganglia involvement in temporal lobe epilepsy: a functional and morphologic study.
Topics: Adolescent; Adult; Basal Ganglia; Basal Ganglia Diseases; Dihydroxyphenylalanine; Dopamine; Down-Reg | 2008 |
Geriatric men at altitude: hypoxic ventilatory sensitivity and blood dopamine changes.
Topics: Adaptation, Physiological; Adult; Age Factors; Aging; Altitude; Analysis of Variance; Dihydroxypheny | 2000 |
85 other studies available for dihydroxyphenylalanine and Sensitivity and Specificity
| Article | Year |
|---|---|
Hybrid [
Topics: Brain Neoplasms; Dihydroxyphenylalanine; Follow-Up Studies; Glioma; Humans; Magnetic Resonance Imagi | 2022 |
18 F-FDOPA and MRI Findings in a Case of Multiple Sclerosis.
Topics: Adult; Brain Neoplasms; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Humans; Magnetic Res | 2022 |
Head-to-Head Comparison Between Rabbit Sign and EANM/SNMMI Criteria for the 18F-DOPA Visual Assessment of Parkinsonian Syndromes in PET/MRI: A Multiple Expert-Based and Blinded Controlled Study.
Topics: Animals; Dihydroxyphenylalanine; Humans; Magnetic Resonance Imaging; Parkinsonian Disorders; Positro | 2023 |
Added value of [
Topics: Brain Neoplasms; Dihydroxyphenylalanine; Glioma; Humans; Neoplasm Recurrence, Local; Positron-Emissi | 2023 |
Diagnostic value of fusion of metabolic and structural images for stereotactic biopsy of brain tumors without enhancement after contrast medium injection.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Biopsy; Brain Neoplasms; Child; Contrast Media; Dihydrox | 2019 |
The impact of 18F-FDOPA-PET/MRI image fusion in detecting liver metastasis in patients with neuroendocrine tumors of the gastrointestinal tract.
Topics: Adult; Aged; Aged, 80 and over; Diffusion Tensor Imaging; Dihydroxyphenylalanine; Female; Gastrointe | 2020 |
Comparison of 18F-DOPA Versus 68Ga-DOTATOC as Preferred PET Imaging Tracer in Well-Differentiated Neuroendocrine Neoplasms.
Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neuroendocrine Tumors; Octreotide; | 2021 |
18F-FDOPA PET Imaging in Prolactinoma.
Topics: Dihydroxyphenylalanine; Humans; Male; Middle Aged; Pituitary Neoplasms; Positron-Emission Tomography | 2017 |
Quantitative analysis of normal and pathologic adrenal glands with 18F-FDOPA PET/CT: focus on pheochromocytomas.
Topics: Adrenal Gland Neoplasms; Adrenal Glands; Adrenalectomy; Diagnosis, Differential; Dihydroxyphenylalan | 2017 |
A novel fluorescence biosensor for sensitivity detection of tyrosinase and acid phosphatase based on nitrogen-doped graphene quantum dots.
Topics: Acid Phosphatase; Ascorbic Acid; Benzoquinones; Biosensing Techniques; Dihydroxyphenylalanine; Fluor | 2018 |
A fluorescent sensor for detecting dopamine and tyrosinase activity by dual-emission carbon dots and gold nanoparticles.
Topics: Benzoquinones; Biological Assay; Dihydroxyphenylalanine; Dopamine; Flocculation; Fluorescence Recove | 2018 |
[
Topics: Adult; Aged; Carcinoma, Neuroendocrine; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; P | 2018 |
Medullary Thyroid Carcinoma: Do Ultrasonography and F-DOPA-PET-CT Influence the Initial Surgical Strategy?
Topics: Adolescent; Adult; Aged; Calcitonin; Carcinoma, Neuroendocrine; Child; Clinical Decision-Making; Dih | 2018 |
18F-FDOPA PET Compared With 123I-Metaiodobenzylguanidine Scintigraphy and 18F-FDG PET in Secreting Sporadic Pheochromocytoma.
Topics: 3-Iodobenzylguanidine; Adrenal Gland Neoplasms; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Huma | 2019 |
Comparative diagnostic accuracy of contrast-enhanced MRI and (18)F-FDOPA PET-CT in recurrent glioma.
Topics: Adult; Brain Neoplasms; Contrast Media; Dihydroxyphenylalanine; Female; Glioma; Humans; Image Proces | 2013 |
Observations on the effects of lithium on carcinoid tumors.
Topics: Bone Neoplasms; Carcinoid Tumor; Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Lithium Com | 2013 |
High-grade glioma radiation therapy target volumes and patterns of failure obtained from magnetic resonance imaging and 18F-FDOPA positron emission tomography delineations from multiple observers.
Topics: Adult; Aged; Astrocytoma; Brain Neoplasms; Contrast Media; Dihydroxyphenylalanine; Female; Fluorine | 2013 |
(18)F-FDOPA PET for differentiating recurrent or progressive brain metastatic tumors from late or delayed radiation injury after radiation treatment.
Topics: Adult; Aged; Brain Neoplasms; Diagnosis, Differential; Dihydroxyphenylalanine; Disease Progression; | 2014 |
Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Dihydroxyphenylalanine; Female; Glioma; Humans; India; Ma | 2014 |
Simulation-based partial volume correction for dopaminergic PET imaging: Impact of segmentation accuracy.
Topics: Artifacts; Brain; Computer Simulation; Dihydroxyphenylalanine; Dopamine; Image Enhancement; Image In | 2015 |
Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery.
Topics: Adult; Aged; Aged, 80 and over; Brain Neoplasms; Diagnosis, Differential; Dihydroxyphenylalanine; Fe | 2015 |
Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
Topics: Adolescent; Brain; Child; Child, Preschool; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; | 2015 |
Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
Topics: Adolescent; Brain; Child; Child, Preschool; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; | 2015 |
Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
Topics: Adolescent; Brain; Child; Child, Preschool; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; | 2015 |
Diagnostic and prognostic value of 18F-DOPA PET and 1H-MR spectroscopy in pediatric supratentorial infiltrative gliomas: a comparative study.
Topics: Adolescent; Brain; Child; Child, Preschool; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; | 2015 |
A family with pheochromocytoma-paraganglioma inherited tumour syndrome. Serial 18F-DOPA PET/CT investigations.
Topics: Adult; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neoplastic Syndromes, Hereditary; | 2016 |
Clinical Value of 18F-fluorodihydroxyphenylalanine Positron Emission Tomography/Contrast-enhanced Computed Tomography (18F-DOPA PET/CT) in Patients with Suspected Paraganglioma.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; False Negative Reactions; Female; Huma | 2016 |
Multiparametric evaluation of low grade gliomas at follow-up: comparison between diffusion and perfusion MR with (18)F-FDOPA PET.
Topics: Adult; Aged; Brain Neoplasms; Diffusion Magnetic Resonance Imaging; Dihydroxyphenylalanine; Female; | 2016 |
Effect of Carbidopa on 18F-FDOPA Uptake in Insulinoma: From Cell Culture to Small-Animal PET Imaging.
Topics: Animals; Carbidopa; Cell Line, Tumor; Dihydroxyphenylalanine; Female; Image Enhancement; Insulinoma; | 2017 |
18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience.
Topics: Adult; Aged; Brain Neoplasms; Dihydroxyphenylalanine; Female; Glioma; Humans; Image Enhancement; Mag | 2009 |
3,4-Dihydroxyphenylalanine gel diffusion assay for polyphenol oxidase quantification.
Topics: Catechol Oxidase; Diffusion; Dihydroxyphenylalanine; Gels; Linear Models; Oxidation-Reduction; Repro | 2008 |
Classification of schizophrenic patients and healthy controls using [18F] fluorodopa PET imaging.
Topics: Adult; Aged; Brain; Control Groups; Corpus Striatum; Dihydroxyphenylalanine; Female; Fluorine Radioi | 2008 |
Direct comparison of FP-CIT SPECT and F-DOPA PET in patients with Parkinson's disease and healthy controls.
Topics: Adult; Aged; Brain; Case-Control Studies; Dihydroxyphenylalanine; Dopamine Plasma Membrane Transport | 2009 |
Intraindividual comparison of 68Ga-DOTA-TATE and 18F-DOPA PET in patients with well-differentiated metastatic neuroendocrine tumours.
Topics: Adult; Aged; Dihydroxyphenylalanine; Female; Gallium Radioisotopes; Humans; Male; Middle Aged; Neopl | 2009 |
The value of 18F-DOPA PET-CT in patients with medullary thyroid carcinoma: comparison with 18F-FDG PET-CT.
Topics: Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Humans; Male; Middle Aged; Positron-Emission | 2009 |
18F-FDOPA PET and PET/CT accurately localize pheochromocytomas.
Topics: Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; Female; Humans; Image Enhancement; Mal | 2009 |
6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine exces
Topics: 3-Iodobenzylguanidine; Adolescent; Adrenal Gland Neoplasms; Adrenal Glands; Adult; Aged; Biomarkers; | 2009 |
PET imaging of medullary thyroid carcinoma in MEN2A transgenic mice using 6-[(18)F]F-L-DOPA.
Topics: Animals; Carcinoma, Medullary; Dihydroxyphenylalanine; Mice; Mice, Transgenic; Multiple Endocrine Ne | 2010 |
(68)Ga-somatostatin analogues PET and (18)F-DOPA PET in medullary thyroid carcinoma.
Topics: Carcinoma, Medullary; Dihydroxyphenylalanine; Humans; Neoplasm Recurrence, Local; Organometallic Com | 2010 |
Value of 18F-fluoro-L-dopa PET in the preoperative localization of focal lesions in congenital hyperinsulinism.
Topics: Congenital Hyperinsulinism; Diagnostic Errors; Dihydroxyphenylalanine; Female; Humans; Image Interpr | 2009 |
Clinical value of 18F-fluorodihydroxyphenylalanine positron emission tomography/computed tomography (18F-DOPA PET/CT) for detecting pheochromocytoma.
Topics: Adolescent; Adult; Aged; Biological Transport; Child; Dihydroxyphenylalanine; Endocrine Gland Neopla | 2010 |
[Recurrent carcinoid tumor and 18F-DOPA PET].
Topics: Biomarkers, Tumor; Carcinoid Tumor; Colonic Neoplasms; Dihydroxyphenylalanine; Fluorine Radioisotope | 2010 |
Utility of various functional and anatomic imaging modalities for detection of ectopic adrenocorticotropin-secreting tumors.
Topics: ACTH Syndrome, Ectopic; Adult; Aged; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Humans; | 2010 |
Dual PET/CT with (18)F-DOPA and (18)F-FDG in metastatic medullary thyroid carcinoma and rapidly increasing calcitonin levels: Comparison with conventional imaging.
Topics: Adult; Aged; Biomarkers, Tumor; Calcitonin; Carcinoma, Medullary; Chi-Square Distribution; Dihydroxy | 2010 |
Comparative evaluation of F-18 FDOPA, F-18 FDG, and F-18 FLT-PET/CT for metabolic imaging of low grade gliomas.
Topics: Adolescent; Adult; Brain Neoplasms; Child; Child, Preschool; Dideoxynucleosides; Dihydroxyphenylalan | 2009 |
Value of combined 6-[18F]fluorodihydroxyphenylalanine PET/CT for imaging of neuroendocrine tumours.
Topics: Adult; Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Humans; Male; Middle Aged; Neuroendo | 2010 |
Clinical value of a combined multi-phase contrast enhanced DOPA-PET/CT in neuroendocrine tumours with emphasis on the diagnostic CT component.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Contrast Media; Dihydroxyphenylalanine; Female; Humans; | 2011 |
Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas.
Topics: Adult; Aged; Brain Neoplasms; Dihydroxyphenylalanine; Glioma; Humans; Male; Middle Aged; Neoplasm Re | 2010 |
Joint factor and kinetic analysis of dynamic FDOPA PET scans of brain cancer patients.
Topics: Algorithms; Brain Neoplasms; Computer Simulation; Dihydroxyphenylalanine; Factor Analysis, Statistic | 2010 |
Sensitivity of kinetic macro parameters to changes in dopamine synthesis, storage, and metabolism: a simulation study for [¹⁸F]FDOPA PET by a model with detailed dopamine pathway.
Topics: Animals; Brain; Dihydroxyphenylalanine; Dopamine; Levodopa; Linear Models; Macaca fascicularis; Mode | 2011 |
Diagnostic accuracy of [¹⁸F]-fluoro-L-dihydroxyphenylalanine positron emission tomography scan for persistent congenital hyperinsulinism in Japan.
Topics: Asian People; Child, Preschool; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Fluorine Radiois | 2011 |
Usefulness of [18F]-DA and [18F]-DOPA for PET imaging in a mouse model of pheochromocytoma.
Topics: Adrenal Gland Neoplasms; Animals; Contrast Media; Dihydroxyphenylalanine; Dopamine; Female; Liver Ne | 2012 |
PET/CT using ¹⁸F-FDOPA provides improved staging of carcinoid tumor patients in a Canadian setting.
Topics: Adult; Aged; Aged, 80 and over; Canada; Carcinoid Tumor; Dihydroxyphenylalanine; Female; Fluorine Ra | 2012 |
The food reaching test: a sensitive test of behavioral improvements by deep brain stimulation in MPTP-treated monkey.
Topics: Animals; Carbon Radioisotopes; Cocaine; Corpus Striatum; Deep Brain Stimulation; Dihydroxyphenylalan | 2012 |
Characterization of neuroblastic tumors using 18F-FDOPA PET.
Topics: 3-Iodobenzylguanidine; Biological Transport; Carboxy-Lyases; Catecholamines; Dihydroxyphenylalanine; | 2013 |
High incidence of extraadrenal paraganglioma in families with SDHx syndromes detected by functional imaging with [18F]fluorodihydroxyphenylalanine PET.
Topics: Adolescent; Adult; Child; Dihydroxyphenylalanine; False Negative Reactions; Female; Germ-Line Mutati | 2013 |
Simultaneous determination of dopa and carbidopa enantiomers by capillary zone electrophoresis.
Topics: Carbidopa; Cyclodextrins; Dihydroxyphenylalanine; Electrophoresis, Capillary; Hydrogen-Ion Concentra | 2002 |
[On the purification and specificity of DOPA-decarboxylase].
Topics: Dihydroxyphenylalanine; Dopa Decarboxylase; Lyases; Sensitivity and Specificity | 1959 |
Correlation of dopamine transporter imaging with parkinsonian motor handicap: how close is it?
Topics: Activities of Daily Living; Aged; Brain; Cocaine; Corpus Striatum; Diagnosis, Differential; Dihydrox | 2003 |
Chiral electrochemical recognition by very thin molecularly imprinted sol-gel films.
Topics: Adsorption; Dihydroxyphenylalanine; Electrochemistry; Electrodes; Ferrous Compounds; Gels; Membranes | 2005 |
Comparison of [18F]FDOPA, [18F]FMT and [18F]FECNT for imaging dopaminergic neurotransmission in mice.
Topics: Animals; Corpus Striatum; Dihydroxyphenylalanine; Dopamine; Male; Mice; Mice, Inbred C57BL; Neurotra | 2006 |
18F-DOPA PET/CT and neuroendocrine tumours.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Neuroendocrine Tumors; Positron-Emission Tom | 2006 |
Can fluorodihydroxyphenylalanine PET replace somatostatin receptor scintigraphy in patients with digestive endocrine tumors?
Topics: Adult; Aged; Carcinoid Tumor; Digestive System Neoplasms; Dihydroxyphenylalanine; Endocrine Gland Ne | 2006 |
[Gastroenteropancreatic neuroendocrine tumours (carcinoid tumours): definition, clinical aspects, diagnosis and therapy].
Topics: Carcinoid Tumor; Dihydroxyphenylalanine; Gastrointestinal Neoplasms; Humans; Pancreatic Neoplasms; P | 2006 |
PET scanning for infants with HHI: a small step for affected infants, a giant leap for the field.
Topics: Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; Infant, Newborn; Male; P | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan.
Topics: Confidence Intervals; Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; In | 2007 |
Diagnostic impact of PET with 18F-FDG, 18F-DOPA and 3-O-methyl-6-[18F]fluoro-DOPA in recurrent or metastatic medullary thyroid carcinoma.
Topics: Adult; Aged; Carcinoma, Medullary; Dihydroxyphenylalanine; Female; Fluorodeoxyglucose F18; Humans; M | 2007 |
The added value of [18F]fluoro-L-DOPA PET in the diagnosis of hyperinsulinism of infancy: a retrospective study involving 49 children.
Topics: Congenital Hyperinsulinism; Dihydroxyphenylalanine; Female; Humans; Infant; Infant, Newborn; Male; P | 2007 |
Compact microelectrode array system: tool for in situ monitoring of drug effects on neurotransmitter release from neural cells.
Topics: Animals; Biosensing Techniques; Collagen; Dihydroxyphenylalanine; Dopamine; Dopamine Agents; Electro | 2008 |
Determination of enantiomeric compositions of DOPA by tandem mass spectrometry using the kinetic method with fixed ligands.
Topics: Algorithms; Computer Simulation; Copper; Dihydroxyphenylalanine; Ligands; Models, Chemical; Molecula | 2008 |
Biomarkers to detect central dopamine deficiency and distinguish Parkinson disease from multiple system atrophy.
Topics: 3,4-Dihydroxyphenylacetic Acid; Analysis of Variance; Biomarkers; Brain; Dihydroxyphenylalanine; Dop | 2008 |
Improved staging of patients with carcinoid and islet cell tumors with 18F-dihydroxy-phenyl-alanine and 11C-5-hydroxy-tryptophan positron emission tomography.
Topics: 5-Hydroxytryptophan; Adenoma, Islet Cell; Adult; Aged; Carbon Radioisotopes; Carcinoid Tumor; Dihydr | 2008 |
68Ga-DOTA-peptides versus 18F-DOPA PET for the assessment of NET patients.
Topics: Dihydroxyphenylalanine; Humans; Neuroendocrine Tumors; Organometallic Compounds; Positron-Emission T | 2008 |
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Topics: Aged; Aged, 80 and over; Dihydroxyphenylalanine; Female; Gastrointestinal Neoplasms; Humans; Lung Ne | 2008 |
A standardized test for the identification and characterization of melanins using electron paramagnetic resonance (EPR) spectroscopy.
Topics: Chemistry Techniques, Analytical; Dihydroxyphenylalanine; Electron Spin Resonance Spectroscopy; Free | 1993 |
Assay for tyrosine hydroxylation activity of tyrosinase from betalain-forming plants and cell cultures.
Topics: Betalains; Cells, Cultured; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Evaluation | 1996 |
Determination of alpha-methyldopa in human plasma by validated high-performance liquid chromatography with fluorescence detection.
Topics: Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Humans; Indicators and Reagents; Methy | 1996 |
Fluorodopa positron emission tomography with an inhibitor of catechol-O-methyltransferase: effect of the plasma 3-O-methyldopa fraction on data analysis.
Topics: Adult; Aged; Catechol O-Methyltransferase Inhibitors; Catechols; Chromatography, High Pressure Liqui | 1996 |
Tyrosine hydroxylase assay for detection of low levels of enzyme activity in peripheral tissues.
Topics: Animals; Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Male; Organ Specificity; PC12 | 1997 |
Determination of serotonin, catecholamines and their metabolites by direct injection of supernatants from chicken brain tissue homogenate using liquid chromatography with electrochemical detection.
Topics: 3,4-Dihydroxyphenylacetic Acid; Animals; Brain Chemistry; Catecholamines; Chickens; Chromatography, | 1997 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Measuring the rate of progression and estimating the preclinical period of Parkinson's disease with [18F]dopa PET.
Topics: Aged; Case-Control Studies; Caudate Nucleus; Dihydroxyphenylalanine; Disease Progression; Humans; Li | 1998 |
Parkinson's disease in twins.
Topics: Dihydroxyphenylalanine; Diseases in Twins; False Negative Reactions; False Positive Reactions; Human | 2000 |
Quantitative PET studies in pretreated melanoma patients: a comparison of 6-[18F]fluoro-L-dopa with 18F-FDG and (15)O-water using compartment and noncompartment analysis.
Topics: Dihydroxyphenylalanine; Fluorodeoxyglucose F18; Humans; Melanoma; Models, Theoretical; Oxygen Radioi | 2001 |
Whole-body 18F dopa PET for detection of gastrointestinal carcinoid tumors.
Topics: Adult; Aged; Carcinoid Tumor; Dihydroxyphenylalanine; Female; Fluorine Radioisotopes; Fluorodeoxyglu | 2001 |
A highly sensitive method for the determination of protein bound 3,4-dihydroxyphenylalanine as a marker for post-translational protein hydroxylation in human tissues ex vivo.
Topics: Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Electrochemistry; Erythrocytes; Fronta | 2001 |
Pheochromocytomas: detection with 18F DOPA whole body PET--initial results..
Topics: Adolescent; Adrenal Gland Neoplasms; Adult; Aged; Dihydroxyphenylalanine; Female; Fluorine Radioisot | 2002 |
Aspects of 6-[18F]fluoro-L-DOPA preparation: precursor synthesis, preparative HPLC purification and determination of radiochemical purity.
Topics: Chromatography, High Pressure Liquid; Dihydroxyphenylalanine; Models, Chemical; Quality Control; Rad | 2002 |
A tyrosine hydroxylase assay in microwells using coupled nonenzymatic decarboxylation of dopa.
Topics: Animals; Brain; Carbon Dioxide; Carbon Radioisotopes; Culture Techniques; Decarboxylation; Dihydroxy | 1991 |